Proposal for BAY 11-7082 (IKK/NF-κB inhibitor)

Overview of Therapeutic Candidate:
BAY 11-7082 is a synthetic small molecule originally synthesized in 1968 that belongs to the class of covalent inhibitors targeting the NF-κB pathway. Its chemical structure is defined by an electrophilic vinyl sulfone moiety incorporating an α,β-unsaturated sulfonyl group, a typical Michael acceptor functional group that permits irreversible covalent binding to nucleophilic sites—particularly cysteine residues—on target proteins (Bertinaria et al., 2019, pp. 15–21). This compound was initially characterized for its ability to block IκB kinase (IKK) activity and, consequently, prevent the phosphorylation and degradation of IκBα, thereby impeding the nuclear translocation of NF-κB dimers. As such, BAY 11-7082 is commonly used as a tool compound in cell-based assays to study signal transduction pathways in inflammation and has become a prototypical representative of covalent NF-κB inhibitors. Its chemical class has historically been exploited in academic and preclinical settings to dissect inflammatory signaling cascades and has demonstrated utility in models of cancer, neurodegeneration, and immune-mediated diseases (Karin et al., 2004, pp. 1–2; Nakanishi & Toi, 2005, pp. 10–11). By virtue of its well-defined synthetic origins and straightforward chemical characteristics that enable covalent modification, BAY 11-7082 has been extensively utilized to interrogate NF-κB-controlled transcription events that drive the expression of numerous proinflammatory mediators.

Therapeutic History:
BAY 11-7082 has a long precedent as a research tool in the biochemical dissection of inflammatory signaling. It has been extensively employed in vitro at low micromolar concentrations to effectively block NF-κB activation by preventing IκBα phosphorylation in various cell types, including epithelial and immune cells (Bernardo et al., 2012, pp. 21–26). Notably, investigations in celiac disease have demonstrated that untreated patients exhibit elevated NF-κB/DNA binding activity in small intestinal biopsies, with increased nuclear translocation of NF-κB p50/p65 observed in both epithelial and lamina propria mononuclear cells (Abignente, n.d., pp. 86–99). Although BAY 11-7082 itself has not been used directly in clinical trials for celiac disease, its mode of action has been conceptually validated by studies utilizing other NF-κB inhibitors and antioxidants that modulate the same signaling pathway in ex vivo duodenal biopsy models (Bernardo et al., 2012, pp. 21–26). In addition, BAY 11-7082 has been evaluated for its ability to disrupt inflammasome activation in immune cells and, given its NF-κB inhibitory capacity, it has been widely cited in literature addressing inflammation-related barrier dysfunction in gastrointestinal and other barrier disorders (Catalioto et al., 2011, pp. 15–16; Hu et al., 2018, pp. 15–18). Preclinical models of inflammatory diseases, including fibrotic conditions and even certain models of cancer, have benefited from its use as a pharmacologic probe, although its direct application in gastrointestinal diseases such as celiac disease remains to be fully explored. In addition, studies in conditions featuring epithelial barrier dysfunction—including data in intestinal cell lines and preclinical animal models of irritable bowel syndrome—support the notion that agents capable of inhibiting NF-κB activation could ameliorate tight junction disruption, reinforcing the potential translational relevance of BAY 11-7082 (Coles et al., 2021, pp. 1–4; Du et al., 2016, pp. 3–4).

Mechanism of Action:
The primary known mechanism of action for BAY 11-7082 is its covalent inhibition of IκB kinase (IKK), which is a pivotal component of the canonical NF-κB activation pathway. Under physiological conditions, NF-κB is maintained in the cytoplasm in a latent state by binding to inhibitory proteins collectively known as IκB. Upon stimulation by proinflammatory signals such as TNF-α, IL-1β, or even gliadin peptides in the context of celiac disease, IKK phosphorylates IκBα, marking it for ubiquitination and proteasomal degradation. This degradation frees NF-κB, allowing its translocation to the nucleus where it drives the transcription of its target genes, including proinflammatory cytokines, enzymes, and modulators of cell survival (Karin et al., 2004, pp. 1–2). BAY 11-7082 interferes with this process by covalently binding to reactive cysteine residues in the IKK complex, thereby inhibiting its kinase activity and ultimately stabilizing IκBα in the cytoplasm (Nakanishi & Toi, 2005, pp. 10–11). Moreover, there is evidence that BAY 11-7082 also affects upstream components of the NF-κB pathway by modifying key elements of the ubiquitin system. It has been shown to covalently modify E2 ubiquitin-conjugating enzymes—such as Ubc13 and UbcH7—as well as components of the E3 ubiquitin ligase complex, further preventing the formation of polyubiquitin chains required for full IKK activation (Bertinaria et al., 2019, pp. 15–21). This dual capacity to inhibit both kinase-dependent phosphorylation and ubiquitin-mediated signaling events contributes to its potent and sustained blockade of NF-κB activation. Importantly, the inhibitory action of BAY 11-7082 results in decreased nuclear translocation of the NF-κB p65 subunit and a corresponding reduction in transcriptional activity of NF-κB target genes. Among these target genes are those encoding myosin light chain kinase (MLCK) and interleukin-15 (IL-15), both of which have been implicated in mediating epithelial tight junction disruption and consequent barrier loss in the small intestine—a hallmark of celiac disease pathology (Bernardo et al., 2012, pp. 21–26; Catalioto et al., 2011, pp. 15–16). Mechanistic studies in various cellular models have confirmed that exposure to NF-κB activating stimuli results in marked upregulation of inflammatory mediators, and that covalent inhibitors such as BAY 11-7082 can block these events by stabilizing IκBα, thereby preserving normal cellular homeostasis (Cocco et al., 2017, pp. 9–12). Additionally, reports indicate that BAY 11-7082 may also inhibit modulators of the inflammasome, further reinforcing its multifaceted anti-inflammatory profile (Baldwin et al., 2016, pp. 11–14).

Expected Effect:
In the context of celiac disease, it is hypothesized that exposure of intestinal epithelial cells to gliadin fragments, together with a proinflammatory cytokine milieu, leads to robust activation of the NF-κB pathway. This activation results in increased transcription of genes including MLCK and IL-15, which are known to disrupt the expression and organization of tight junction (TJ) proteins such as occludin, claudins, and zona occludens-1 (ZO-1), culminating in compromised epithelial barrier integrity (Abignente, n.d., pp. 86–99; Catalioto et al., 2011, pp. 15–16). BAY 11-7082 is expected to inhibit IKK activity, thereby preventing the phosphorylation and subsequent degradation of IκBα. As a direct consequence, NF-κB remains sequestered in the cytoplasm, and the transcription of NF-κB–dependent genes essential for mediating inflammation and barrier disruption is attenuated (Bernardo et al., 2012, pp. 21–26). In experimental assays using epithelial cells such as Caco-2 monolayers or intestinal organoids, one would anticipate that treatment with BAY 11-7082 will lead to measurable increases in cytosolic IκBα levels and a reduction in nuclear accumulation of NF-κB p65. This biochemical shift is expected to result in lower expression levels of MLCK, reducing its ability to phosphorylate myosin regulatory light chains and thereby maintaining the integrity of the actin cytoskeleton and TJ complexes. Additionally, diminished NF-κB activity should lead to reduced IL-15 transcription, thereby curtailing further inflammatory signals that contribute to barrier dysfunction (Bernardo et al., 2012, pp. 21–26; Catalioto et al., 2011, pp. 15–16). This mechanistic intervention should help restore or preserve the expression and localization of key TJ proteins (e.g., occludin, claudin-1, and ZO-1), normalizing paracellular permeability and ultimately contributing to the maintenance of intestinal barrier function under conditions that normally provoke inflammation, such as exposure to gliadin peptides.

Overall Evaluation:
BAY 11-7082 offers a scientifically compelling approach for repurposing as a therapeutic candidate in celiac disease due to its well-characterized mechanism of covalent IKK inhibition and subsequent blockade of NF-κB activation. The strengths of BAY 11-7082 lie primarily in its ability to interfere with a critical molecular pathway that is directly implicated in the pathogenesis of celiac disease. NF-κB is a master regulator of inflammation, and its activation in intestinal epithelial cells leads to upregulation of mediators such as MLCK and IL-15 that contribute to tight junction disruption and barrier dysfunction (Abignente, n.d., pp. 86–99; Bernardo et al., 2012, pp. 21–26). By inhibiting IKK, BAY 11-7082 has the potential to prevent these deleterious effects on the epithelial barrier, thereby reducing the intestinal permeability and chronic inflammation that are hallmarks of celiac disease. Its use in various in vitro and preclinical models has provided a robust proof-of-concept that modulation of NF-κB can yield beneficial outcomes in contexts of inflammatory injury (Cocco et al., 2017, pp. 9–12; Catalioto et al., 2011, pp. 15–16).

However, several weaknesses and challenges must be carefully considered before advancing BAY 11-7082 further in the development pipeline for celiac disease. A significant concern is its intrinsic electrophilic nature, which, while crucial for its covalent binding to IKK, may also confer a propensity for off-target reactivity. BAY 11-7082 has been documented to interact with other cellular proteins, including various E2 ubiquitin-conjugating enzymes and E3 ligases, leading to broader suppression of ubiquitination-dependent signaling events (Bertinaria et al., 2019, pp. 15–21, 60–63). Such nonselective interactions could induce unintended cytotoxicity or impact other cellular processes critical for normal cell function. In vitro studies have hinted at cytotoxic effects in some cancer cell lines, potentially stemming from these off-target effects, although these data are not directly extrapolatable to nontransformed intestinal epithelial cells (Strickson et al., 2013, pp. 11–14; Rauert-Wunderlich et al., 2013, pp. 1–3).

Furthermore, despite extensive use in cell-based assays, BAY 11-7082 has not been evaluated in clinical trials or well-defined in vivo models of celiac disease. Its pharmacokinetic properties, bioavailability after oral administration, and systemic safety profile in the context of chronic inflammatory diseases remain largely uncharacterized. These issues are of particular importance when considering long-term therapy for a lifelong condition such as celiac disease, where sustained drug exposure could lead to cumulative toxicity if off-target effects are not adequately controlled. Comparatively, the documented evidence supporting the NF-κB pathway’s dysregulation in celiac disease, including elevated nuclear p65 expression and increased expression of NF-κB–dependent mediators, does support the overall therapeutic rationale; yet, the transition from a research tool to a clinically viable drug candidate requires extensive optimization to mitigate these safety concerns (Prescott & Cook, 2018, pp. 6–8; Hu et al., 2018, pp. 15–18).

Another aspect that merits careful attention is the dosage and potential variability in response among different epithelial cell models. Given the complexity of NF-κB signaling and its role in both pro-inflammatory and cell-survival processes, it is crucial to determine whether BAY 11-7082 can achieve sufficient and sustained NF-κB inhibition in intestinal epithelial cells—such as those found in Caco-2 monolayers or patient-derived organoids—without adversely affecting cell viability or function. Preliminary studies in other models have shown that inhibition of NF-κB signaling can indeed normalize TJ protein expression and reduce cytokine production; however, the optimal therapeutic window for BAY 11-7082 in the gastrointestinal context has not been established (Du et al., 2016, pp. 3–4; Scuderi et al., 2020, pp. 9–11).

Moreover, the multifaceted nature of celiac disease pathogenesis, which involves not only epithelial barrier dysfunction but also an adaptive immune response triggered by gliadin peptides in a genetically predisposed background, adds a layer of complexity. In this scenario, solely targeting NF-κB in epithelial cells may not fully address the immunopathological cascades that drive mucosal destruction and villous atrophy. Combination strategies using BAY 11-7082 with other agents—potentially antioxidants, other immunomodulators, or even agents that strengthen tight junctions directly—might be necessary to achieve a robust therapeutic effect. In this context, thoughtful preclinical study design and stratification of responsive patient subsets will be instrumental in assessing whether NF-κB blockade via BAY 11-7082 can modify disease progression in celiac pathology (Abignente, n.d., pp. 86–99; Bernardo et al., 2012, pp. 21–26).

From a biochemical standpoint, the hypothesis that BAY 11-7082 will reduce the transcription of MLCK, IL-15, and other mediators responsible for TJ disruption is supported by evidence indicating that NF-κB drives the expression of these genes in response to inflammatory stimuli. Studies have demonstrated that exposure to gliadin results in sustained NF-κB activation in the small intestine, correlating with increased expression of inflammatory mediators and subsequent barrier dysfunction (Abignente, n.d., pp. 86–99). In parallel, reports documenting that other NF-κB inhibitors and antioxidants, such as ascorbate, can dampen the mucosal immune response further validate the concept that targeted inhibition of NF-κB may lead to the normalization of epithelial barrier function (Bernardo et al., 2012, pp. 21–26; Catalioto et al., 2011, pp. 15–16). Additionally, data from cell models show that tight junction integrity is directly related to the expression levels of MLCK and the phosphorylation state of myosin regulatory light chains, supporting the contention that NF-κB blockade would have a beneficial effect on epithelial barrier properties (Cocco et al., 2017, pp. 9–12). This is particularly important in the context of celiac disease, where increased MLCK expression and subsequent tight junction disassembly contribute to enhanced intestinal permeability and ongoing inflammation.

In summary, BAY 11-7082 represents a promising candidate for repurposing in celiac disease on mechanistic grounds. Its ability to act as a covalent inhibitor of IKK and block the NF-κB signaling cascade aligns well with the current understanding of the molecular dysregulation underpinning celiac disease pathogenesis. By inhibiting NF-κB activation, BAY 11-7082 is expected to reduce the expression of key proinflammatory genes, including MLCK and IL-15, which contribute to tight junction disruption and epithelial barrier dysfunction. Its extensive use as a research tool in preclinical settings attests to its potency and robust biochemical profile (Bertinaria et al., 2019, pp. 15–21; Strickson et al., 2013, pp. 10–11).

Nonetheless, significant challenges remain. The potential for off-target effects due to its electrophilic and covalent binding nature raises concerns about cytotoxicity and the inhibition of other essential cellular processes. The lack of extensive in vivo data in models specifically relevant to celiac disease, combined with unknown pharmacokinetic and safety profiles in the gastrointestinal tract, underscores the critical need for further rigorous studies. Detailed dose-response evaluations, assessments of chronic exposure, and the development of more selective analogues could help mitigate some of these concerns. Future research should also explore combination therapeutic strategies that target multiple facets of celiac disease pathology, perhaps pairing BAY 11-7082 with other agents that directly reinforce tight junctions or modulate adaptive immune responses.

From an overall perspective, BAY 11-7082 exhibits significant potential as a repurposed drug candidate for celiac disease based on its well-elucidated biochemical mechanism and its established capacity to block NF-κB signaling—a central driver of inflammation and barrier dysfunction in the disease. Its strengths lie in the solid scientific rationale and the wealth of preclinical data supporting NF-κB’s role in mediating proinflammatory gene expression and tight junction disruption. However, crucial limitations regarding off-target reactivity, potential cytotoxicity, and a dearth of direct in vivo evidence in celiac models must be addressed before clinical translation can be considered. Consequently, while BAY 11-7082 is a promising candidate for further preclinical exploration in intestinal epithelial models challenged with gliadin and proinflammatory cytokines, additional studies focusing on specificity, safety, and optimal dosing are essential to fully validate its potential in the therapeutic landscape of celiac disease (Bernardo et al., 2012, pp. 21–26; Bertinaria et al., 2019, pp. 15–21; Prescott & Cook, 2018, pp. 10–12).

References
Abignente, E. (n.d.). Pathogenetics mechanisms of celiac disease. Unknown journal.

Baldwin, A. G., Brough, D., & Freeman, S. (2016). Inhibiting the inflammasome: A chemical perspective. Journal of Medicinal Chemistry, 59(5), 1691–1710. https://doi.org/10.1021/acs.jmedchem.5b01091

Bernardo, D., Martinez-Abad, B., Vallejo-Díez, S., Montalvillo, E., Benito, V., Anta, B., Fernández-Salazar, L., Blanco-Quirós, A., Garrote, J. A., & Arranz, E. (2012). Ascorbate-dependent decrease of the mucosal immune inflammatory response to gliadin in coeliac disease patients. Allergologia et Immunopathologia, 40, 3–8. https://doi.org/10.1016/j.aller.2010.11.003

Bertinaria, M., Gastaldi, S., Marini, E., & Giorgis, M. (2019). Development of covalent NLRP3 inflammasome inhibitors: Chemistry and biological activity. Archives of Biochemistry and Biophysics, 670, 116–139. https://doi.org/10.1016/j.abb.2018.11.013

Catalioto, R.-M., Maggi, C. A., & Giuliani, S. (2011). Intestinal epithelial barrier dysfunction in disease and possible therapeutic interventions. Current Medicinal Chemistry, 18, 398–426. https://doi.org/10.2174/092986711794839179

Cocco, M., Pellegrini, C., Martínez-Banaclocha, H., Giorgis, M., Marini, E., Costale, A., Miglio, G., Fornai, M., Antonioli, L., López-Castejón, G., Tapia-Abellán, A., Angosto, D., Hafner-Bratkovič, I., Regazzoni, L., Blandizzi, C., Pelegrín, P., & Bertinaria, M. (2017). Development of an acrylate derivative targeting the NLRP3 inflammasome for the treatment of inflammatory bowel disease. Journal of Medicinal Chemistry, 60, 3656–3671. https://doi.org/10.1021/acs.jmedchem.6b01624

Coles, V. E., Darveau, P., Zhang, X., Harvey, H., Henriksbo, B. D., Yang, A., Schertzer, J. D., Magolan, J., & Burrows, L. L. (2021). Exploration of Bay 11-7082 as a novel antibiotic [Preprint]. bioRxiv. https://doi.org/10.1101/2021.09.28.462244

Du, L., Kim, J. J., Shen, J., & Dai, N. (2016). Crosstalk between inflammation and ROCK/MLCK signaling pathways in gastrointestinal disorders with intestinal hyperpermeability. Gastroenterology Research and Practice, 2016, Article 7374197. https://doi.org/10.1155/2016/7374197

Hu, J. J., Liu, X., Zhao, J., Xia, S., Ruan, J., Luo, X., Kim, J., Lieberman, J., & Wu, H. (2018). Identification of pyroptosis inhibitors that target a reactive cysteine in gasdermin D [Preprint]. bioRxiv. https://doi.org/10.1101/365908

Karin, M., Yamamoto, Y., & Wang, Q. M. (2004). The IKK NF-κB system: A treasure trove for drug development. Nature Reviews Drug Discovery, 3, 17–26. https://doi.org/10.1038/nrd1279

Nakanishi, C., & Toi, M. (2005). Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nature Reviews Cancer, 5, 297–309. https://doi.org/10.1038/nrc1588

Prescott, J. A., & Cook, S. J. (2018). Targeting IKKβ in cancer: Challenges and opportunities for the therapeutic utilisation of IKKβ inhibitors. Cells, 7(9), 115. https://doi.org/10.3390/cells7090115

Rauert-Wunderlich, H., Siegmund, D., Maier, E., Giner, T., Bargou, R. C., Wajant, H., & Stühmer, T. (2013). The IKK inhibitor Bay 11-7082 induces cell death independent from inhibition of activation of NFκB transcription factors. PLoS ONE, 8(3), e59292. https://doi.org/10.1371/journal.pone.0059292

Scuderi, S. A., Casili, G., Lanza, M., Filippone, A., Paterniti, I., Esposito, E., & Campolo, M. (2020). Modulation of NLRP3 inflammasome attenuated inflammatory response associated to diarrhea-predominant irritable bowel syndrome. Biomedicines, 8(11), 519. https://doi.org/10.3390/biomedicines8110519

Strickson, S., Campbell, D. G., Emmerich, C. H., Knebel, A., Plater, L., Ritorto, M. S., Shpiro, N., & Cohen, P. (2013). The anti-inflammatory drug Bay 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. Biochemical Journal, 451, 427–437. https://doi.org/10.1042/bj20121651
